Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinsonâs Disease and Mild Cognitive Impairment/early Alzheimerâs disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
äŒæ¥ã³ãŒãJUNS
äŒç€ŸåJupiter Neurosciences Inc
äžå Žæ¥Dec 03, 2024
æé«çµå¶è²¬ä»»è
ãCEOãRosen (Christer)
åŸæ¥å¡æ°4
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Dec 03
æ¬ç€Ÿæåšå°1001 North US HWY 1, Suite 504
éœåžPALM BEACH GARDENS
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·33477
é»è©±çªå·15614066154
ãŠã§ããµã€ãhttps://jupiterneurosciences.com/
äŒæ¥ã³ãŒãJUNS
äžå Žæ¥Dec 03, 2024
æé«çµå¶è²¬ä»»è
ãCEOãRosen (Christer)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã